Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521048 · ClinicalTrials.gov registry record · Phase 1
Doxycycline in Cutaneous Schwannoma (NF2)
A Phase 1 study of Neurofibromatosis Type 2, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT05521048: Active Phase 1 study of Neurofibromatosis Type 2, sponsored by Massachusetts Eye and Ear Infirmary.
NCT05521048 is a Phase 1 study of Neurofibromatosis Type 2 that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521048, a Phase 1 study of Neurofibromatosis Type 2, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.
Primary Outcome
Longitudinal change in tumor maximal diameter
Conditions Studied
Interventions
- DRUG Doxycycline Injection [Doxy]
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05521048 still lists
NCT05521048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Neurofibromatosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Doxycycline Injection [Doxy] is the first listed.
NCT05521048 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05521048 about?
NCT05521048 is a clinical study titled "Doxycycline in Cutaneous Schwannoma (NF2)". In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associate...
What is the current status of trial NCT05521048?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-09-19. Estimated completion is 2026-12.
What conditions does trial NCT05521048 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 2.
What interventions are being tested in trial NCT05521048?
The interventions under investigation include: Doxycycline Injection [Doxy] (DRUG).
Who is sponsoring clinical trial NCT05521048?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05521048 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05521048's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI